Tesamorelin / Ipamorelin
This IPS-listed option is reviewed privately during consultation. Details are reviewed privately during consultation.
Metabolic GH-support stack
A combined body-composition and metabolic-support conversation involving growth-hormone pathway support from Tesamorelin and Ipamorelin plus mitochondrial signaling support from MOTS-c.
Overview
a triple blend combining Tesamorelin for GHRH pathway support, Ipamorelin for selective ghrelin-receptor GH signaling, and MOTS-c for mitochondrial and AMPK-related metabolic support.
IPS does not currently show one exact Tesa/IPA/MOTS-c triple-blend card. The available list lists related options including Tesamorelin / Ipamorelin, MOTS-C, and MOTs-C/Tesamorelin.
IPS access
These entries come from the IPS access available list. Final route, timing, duration, and candidacy depend on consultation, availability, and clinician judgment.
This IPS-listed option is reviewed privately during consultation. Details are reviewed privately during consultation.
This IPS-listed option is reviewed privately during consultation. Details are reviewed privately during consultation.
This IPS-listed option is reviewed privately during consultation. Details are reviewed privately during consultation.
Mechanism
This stack is commonly framed around three complementary ideas: GHRH signaling, ghrelin-receptor amplification, and AMPK-related mitochondrial support. IPS translates that into practical screening, lab review, and measurable outcomes.
A GHRH analog discussed for growth-hormone support and body-composition conversations.
Often discussed for selective GH secretion through ghrelin-receptor activity.
A mitochondrial-derived peptide discussed around AMPK, glucose metabolism, and cellular energy.
Nutrition, strength training, sleep, metabolic labs, and medication review remain central.
Process
Review body composition, waist changes, energy, sleep, training, nutrition, glucose markers, and medications.
Screen cancer history, pituitary history, diabetes medications, sleep apnea risk, pregnancy-related factors, and lab needs.
If appropriate, your clinician reviews related listings, route, timing, frequency, and monitoring expectations.
Follow-up tracks tolerance, labs, body-composition trends, sleep, energy, and recovery.
Safety & candidacy
IPS reviews IGF-1 context, glucose status, diabetes or GLP-1 medication use, cancer history, pituitary history, cardiovascular symptoms, sleep apnea risk, pregnancy-related factors where applicable, and whether labs are needed.
Questions
The current available list does not show one exact triple-blend card. It lists Tesamorelin / Ipamorelin, MOTS-C, and MOTs-C/Tesamorelin as related options.
The reference blend pairs GH pathway support with mitochondrial and metabolic signaling for body-composition and recovery conversations.
No. It is discussed for metabolic and GH-support education. Weight goals should be reviewed with nutrition, training, labs, and medical history.
No. Medication changes and diabetes care should be managed by the prescribing clinician.
Contact
Complete the form and IPS will follow up about consultation scheduling and next steps.